Nutritional benefits of flavocoxid in patients with osteoarthritis: efficacy and safety

References

• Liu Y, Wang MW. Botanical drugs: challenges and opportunities: contribution to Linnaeus Memorial Symposium 2007. Life Sci. 2008;82(9–10):445–449.
   PubMed Web of Science ®Google Scholar
• Farnsworth NR. The role of ethnopharmacology in drug development [discussion]. Ciba Found Symp. 1990;154:2–11; discussion 11–21.
   PubMedGoogle Scholar
• Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001;109 Suppl 1:69–75.
   Google Scholar
• Adegbehingbe OO, Adesanya SA, Idowu TO, Okimi OC, Oyelami OA, Iwalewa EO. Clinical effects of Garcinia kola in knee osteoarthritis. JOrthop SurgRes. 2008;3:34.
   PubMedGoogle Scholar
• Farid R, Mirfeizi Z, Mirheidari M, et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutr Res. 2007;27:692–697.
   Web of Science ®Google Scholar
• Cisar P, Jany R, Waczulikova I, et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res. 2008;22(8):1087–1092.
   PubMed Web of Science ®Google Scholar
• Belcaro G, Cesarone MR, Errichi S, et al. Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance, and vascular aspects. Phytother Res. 2008;22(4):518–523.
   PubMed Web of Science ®Google Scholar
• Lozada CJ, Altman RD. . Management of osteoarthritis. In: Koopman Wj, ed. Arthritis and Related Conditions. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2001:2246.
   Google Scholar
• Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987;30(8):914–918.
   PubMed Web of Science ®Google Scholar
• Claessens AA, Schouten JS, van den Ouweland FA, Valkenburg HA. Do clinical findings associate with radiographic osteoarthritis of the knee? Ann Rheum Dis. 1990;49(10):771–774.
   Google Scholar
• Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001;60(2):91–97.
   PubMed Web of Science ®Google Scholar
• Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006;354(8):841–848.
   PubMed Web of Science ®Google Scholar
• Bolin J, Helmick CG, Sacks JJ, Langmaid G; Center for Chronic Disease Prevention and Health Promotion. Prevalence of self-reported arthritis or chronic joint symptoms among adults – United States, 2001. MMWR Morbid Mortal Wkly Rep. 2002;51(42):948–950.
   Google Scholar
• Pleis JR, Lethbridge-Cejku M. Summary health statistics for US adults: National Health Interview Survey, 2006. Vital Health Stat 10. 2007(235):1–153.
   Google Scholar
• Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–656.
   PubMed Web of Science ®Google Scholar
• Odding E, Valkenburg HA, Algra D, Vandenouweland FA, Grobbee DE, Hofman A. Associations of radiological osteoarthritis of the hip and knee with locomotor disability in the Rotterdam Study. Ann Rheum Dis. 1998;57(4):203–208.
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. JOccup Environ Med. 2008;50(9): 998–1005.
   Google Scholar
• De Filippis L, Gulli S, Caliri A, et al. [Epidemiology and risk factors in osteoarthritis: literature review data from “OASIS” study]. Reumatismo. 2004;56(3):169–184. Italian.
   PubMedGoogle Scholar
• Rabenda V Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 2006;33(6):1152–1158.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, Campion ME, O’Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol. 1997; 24(4):719–725.
   PubMed Web of Science ®Google Scholar
• Van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis. 1989;48(4):271–280.
   PubMed Web of Science ®Google Scholar
• Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford). 2002;41 Suppl 1:3–6.
   Google Scholar
• McAlindon TE, Snow S, Cooper C, Dieppe PA. Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis. 1992; 51(7):844–849.
   PubMed Web of Science ®Google Scholar
• Dannhardt G, Kiefer W Cyclooxygenase inhibitors – current status and future prospects. Eur J Med Chem. 2001;36(2):109–126.
   PubMed Web of Science ®Google Scholar
• Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis: a review. J Knee Surg. 2006;19(3):191–197.
   PubMedGoogle Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15.
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18(7):790–804.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21):1520–1528.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–2073.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–1091.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–1255.
   PubMed Web of Science ®Google Scholar
• Wallace JL. Nonsteroidal anti-inflammatory drugs and gastro- enteropathy: the second hundred years. Gastroenterology. 1997; 112(3):1000–1016.
   Google Scholar
• Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167(10):1131–1137.
   Web of Science ®Google Scholar
• Deschner J, Hofman CR, Piesco NP, Agarwal S. Signal transduction by mechanical strain in chondrocytes. Curr Opin Clin Nutr Metab Care. 2003;6(3):289–293.
   PubMed Web of Science ®Google Scholar
• Westacott CI, Urban JP, Goldring MB, Elson CJ. The effects of pressure on chondrocyte tumor necrosis factor receptor expression. Biorheol- ogy. 2002;39(1–2):125–132.
   Web of Science ®Google Scholar
• Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol. 2003;15(5):623–627.
   Google Scholar
• Pantano C, Reynaert NL, van der Vliet A, Janssen-Heininger YM. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. AntioxidRedox Signal. 2006;8(9–10):1791–1806.
   PubMed Web of Science ®Google Scholar
• Bonizzi G, Piette J, Merville MP, Bours V Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1. Biochem Pharmacol. 2000;59(1):7–11.
   Google Scholar
• Vincenti MP, Brinckerhoff CE. Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin- 1beta. Arthritis Res. 2001;3(6):381–388.
   PubMedGoogle Scholar
• Kopp EB, Ghosh S. NF-kappa B and rel proteins in innate immunity. Adv Immunol. 1995;58:1–27.
   PubMed Web of Science ®Google Scholar
• Baldwin AS. The transcription factor NF-kB and human disease. J Clin Invest. 2001;107:3–6.
   PubMed Web of Science ®Google Scholar
• Perkins ND. Integrating cell-signaling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49–62.
   PubMed Web of Science ®Google Scholar
• Pahl HL. Activators and target genes of rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6853–6866.
   PubMed Web of Science ®Google Scholar
• Scheiman JM. Outcomes studies of the gastrointestinal safety of cycloox- ygenase-2 inhibitors. Cleve Clin J Med. 2002;69 Suppl 1: SI40-S146.
   Web of Science ®Google Scholar
• Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res. 2001;43:429–436.
   PubMed Web of Science ®Google Scholar
• Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34:742–747.
   PubMed Web of Science ®Google Scholar
• Rainsford KD. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Inflamm Res. 1993;39 Suppl 1:C24–C26.
   Google Scholar
• Obase Y, Matsuse H, Shimoda T, Haahtela T, Kohno S. Pathogenesis and management of aspirin-intolerant asthma. Treat Respir Med. 2005;4(5):325–336.
   PubMedGoogle Scholar
• Babu KS, Salvi SS. Aspirin and asthma. Chest. 2000;118(5):1470–1476.
   PubMed Web of Science ®Google Scholar
• Berti F, Rossoni G, Magni F, et al. Nonsteroidal antiinflammatory drugs aggravate acute myocardial ischemia in the perfused rabbit heart: a role for prostacyclin. J Cardiovasc Pharmacol. 1988;12(4):438–444.
   Google Scholar
• Marcouiller P, Pelletier JP, Guevremont M, et al. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. J Rheumatol. 2005;32(4):704–712.
   PubMed Web of Science ®Google Scholar
• Sprecher HW, Baykousheva SP, Luthria DL, Mohammed BS. Differences in the regulation of biosynthesis of 20- versus 22-carbon polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 1995;52(2–3):99–101.
   Google Scholar
• Lippiello L, Walsh T, Fienhold M. The association of lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. Metabolism. 1991;40(6):571–576.
   Google Scholar
• Lippiello L. Lipid and cell metabolic changes associated with essential fatty acid enrichment of articular chondrocytes. Proc Soc Exp Biol Med. 1990;195(2):282–227.
   Google Scholar
• Plumb MS, Aspden RM. High levels of fat and (n-6) fatty acids in cancellous bone in osteoarthritis. Lipids Health Dis. 2004;3:12.
   Google Scholar
• Xu H, Watkins BA, Adkisson HD. Dietary lipids modify the fatty acid composition of cartilage, isolated chondrocytes and matrix vesicles. Lipids Health Dis. 1994;29:619–625.
   Google Scholar
• Hart DJ, Doyle DV, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol. 1995;22(6):1118–1123.
   Google Scholar
• McAlindon T, Zhang Y, Hannan M, et al. Are risk factors for patel- lofemoral and tibiofemoral knee osteoarthritis different? J Rheumatol. 1996;23(2):332–337.
   Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Moreland L, Desomond R, Kendrach A. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Med Food. 2008;12:1–6.
   Web of Science ®Google Scholar
• Jia Q. Generating and screening a natural product library for cyclooxygenase and lipoxygenase dual inhibitors. Stud Nat Prod Chem. 2003;29:643–718.
   Google Scholar
• Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007;50(7):1425–1441.
   PubMed Web of Science ®Google Scholar
• Dietz R, Nastainczyk W, Ruf HH. Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2. Eur J Biochem. 1988;171(1–2):321–328.
   Google Scholar
• Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food. 2007;10(3):442–451.
   PubMed Web of Science ®Google Scholar
• Kulmacz RJ, Lands WE. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem. 1985;260(23):12572–12578.
   Google Scholar
• Callan OH, So OY, Swinney DC. The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J Biol Chem. 1996;271(7):3548–3554.
   Google Scholar
• Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Brit J Pharmacol. 2009;157(8):1410–1418.
   PubMed Web of Science ®Google Scholar
• Schafer H, Schafer A, Kiderlen AF, Masihi KN, Burger R. A highly sensitive cytotoxicity assay based on the release of reporter enzymes, from stably transfected cell lines. J Immunol Methods. 1997;204(1):89–98.
   Web of Science ®Google Scholar
• Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983;113:173–215.
   PubMed Web of Science ®Google Scholar
• Gatehouse D, Haworth S, Cebula T, et al. Recommendations for the performance of bacterial mutation assays. Mutat Res. 1994;312:217–233.
   PubMed Web of Science ®Google Scholar
• Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica. 1999;29(1):53–75.
   PubMed Web of Science ®Google Scholar
• Burnett BP, Silva S, Mesches MH, Jia Q. Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem. 2007;31:797–825.
   Google Scholar
• Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84–112.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389–430.
   PubMed Web of Science ®Google Scholar
• Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4):219–244.
   PubMedGoogle Scholar
• Elliott GA, Purmalis A, Vandermeer DA, Denlinger RH. The propionic acids. Gastrointestinal toxicity in various species. Toxicol Pathol. 1988;16(2):245–250.
   Google Scholar
• Parmar NS, Parmar S. Anti-ulcer potential of flavonoids. Indian J Physiol Pharmacol. 1998;42(3):343–351.
   Google Scholar
• Escrig V, Ubeda A, Ferrandiz ML, et al. Variabilin: a dual inhibitor of human secretory and cytosolic phospholipase A2 with anti-inflammatory activity. J Pharmacol Exp Ther. 1997;282(1): 123–131.
   Google Scholar
• Carlson RP, O’Neill-Davis L, Chang J, Lewis AJ. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Inflamm Res. 1985;17(2): 197–204.
   Google Scholar
• Burnett BP, Stenstrom KK, Baarsch MJ, Swafford WS, Ehrenzweig J, Levy RM. A flavonoid mixture, dual inhibitor of cyclooxygenase and 5-lipoxygenase enzymes, shows superiority to glucosamine/chondroitin for pain management in moderate osteoarthritic dogs. Intern J Appl Res Vet Med. 2009;7(1):1–12.
   Google Scholar
• Gee JM, DuPont MS, Rhodes MJ, Johnson IT. Quercetin glucosides interact with the intestinal glucose transport pathway. Free Radic Biol Med. 1998;25(1):19–25.
   PubMed Web of Science ®Google Scholar
• Manach C, Morand C, Texier O, et al. Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J Nutr. 1995; 125(7):1911–1922.
   PubMed Web of Science ®Google Scholar
• Hollman PC, Katan MB. Absorption, metabolism, and health effects of dietary flavonoids in man. Biomed Pharmacother. 1997; 51(8):305–310.
   PubMed Web of Science ®Google Scholar
• Gee JM, DuPont MS, Day AJ, Plumb GW, Williamson G, Johnson IT. Intestinal transport of quercetin glycosides in rats involves both degly- cosylation and interaction with the hexose transport pathway. J Nutr. 2000;130(11):2765–2771.
   PubMed Web of Science ®Google Scholar
• Boulton DW, Walle UK, Walle T. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol. 1998;50(2):243–249.
   Google Scholar
• Akao T, Kawabata K, Yanagisawa E, et al. Baicalin, the predominant flavone glucuronide of Scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol. 2000;52(12):1563–1568.
   PubMed Web of Science ®Google Scholar
• Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J. 1997;11(4):206–216.
   PubMed Web of Science ®Google Scholar
• Piskula MK, Terao J. Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues. J Nutr. 1998;128(7):1172–1178.
   Google Scholar
• Koster H, Halsema I, Scholtens E, Knippers M, Mulder GJ. Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes. The role of saturation of phenolsulfotransferase. Biochem Pharmacol. 1981;30(18):2569–2575.
   Web of Science ®Google Scholar
• Piskula MK. Soy isoflavone conjugation differs in fed and food- deprived rats. J Nutr. 2000;130(7):1766–1771.
   Web of Science ®Google Scholar
• Yim JS, Kim YS, Moon SK, et al. Metabolic activities of ginse- noside Rb1, baicalin, glycyrrhizin, and geniposide to their bioactive compounds by human intestinal microflora. Biol Pharm Bull. 2004;27(10):1580–1583.
   PubMed Web of Science ®Google Scholar
• Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004; 79(5):727–747.
   PubMed Web of Science ®Google Scholar
• Wang LQ, Meselhy MR, Li Y, et al. The heterocyclic ring fission and dehydroxylation of catechins and related compounds by Eubacterium sp. strain SDG-2, a human intestinal bacterium. Chem Pharm Bull (Tokyo). 2001;49(12):1640–1643.
   PubMed Web of Science ®Google Scholar
• Das NP, Griffiths LA. Studies on flavonoid metabolism. Metabolism of (+)-[14C] catechin in the rat and guinea pig. Biochem J. 1969;115(4):831–836.
   Web of Science ®Google Scholar
• Hackett AM, Griffiths LA, Broillet A, Wermeille M. The metabolism and excretion of (+)-[14C] cyanidanol-3 in man following oral administration. Xenobiotica. 1983;13(5):279–286.
   PubMed Web of Science ®Google Scholar
• Bell JR, Donovan JL, Wong R, et al. (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. Am J Clin Nutr. 2000;71(1):103–108.
   PubMed Web of Science ®Google Scholar
• Abe K, Inoue O, Yumioka E. Biliary excretion of metabolites of baicalin and baicalein in rats. Chem Pharm Bull (Tokyo). 1990;38(1):209–211.
   PubMed Web of Science ®Google Scholar
• Lai MY, Hsiu SL, Chen CC, Hou YC, Chao PD. Urinary pharmacokinetics of baicalein, wogonin, and their glycosides after oral administration of Scutellariae radix in humans. Biol Pharm Bull. 2003;26(1):79–83.
   PubMed Web of Science ®Google Scholar
• Lin YS, Tsai YJ, Tsay JS, Lin JK. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J Agric Food Chem. 2003; 51(7):1846–1873.
   Web of Science ®Google Scholar
• Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002;22:19–34.
   PubMed Web of Science ®Google Scholar
• Fiorani M, Accorsi A, Cantoni O. Human red blood cells as a natural flavonoid reservoir. Free Radic Res. 2003;37(12):1331–1338.
   PubMed Web of Science ®Google Scholar
• Fiorani M, Accorsi A. Dietary flavonoids as intracellular substrates for an erythrocyte trans-plasma membrane oxidoreductase activity. Br J Nutr. 2005;94(3):338–345.
   Web of Science ®Google Scholar
• Tang Y, Zhu H, Zhang Y, Huang C. Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography. Biomed Chromatogr. 2006;20(10):1116–1119.
   Web of Science ®Google Scholar
• Diniz A, Escuder-Gilabert L, Lopes NP, Villanueva-Camanas RM, Sagrado S, Medina-Hernandez MJ. Characterization of interactions between polyphenolic compounds and human serum proteins by capillary electrophoresis. Anal Bioanal Chem. 2008;391(2):625–632.
   PubMed Web of Science ®Google Scholar
• Ishihara M, Honma M, Kuno E, Watanabe M, Koda Y [Combination use of kampo-medicines and drugs affecting intestinal bacterial flora]. Yakugaku Zasshi. 2002;122(9):695–701.
   Web of Science ®Google Scholar
• Xing J, Chen X, Sun Y, Luan Y, Zhong D. Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. J Pharm Pharmacol. 2005;57(6):743–750.
   PubMed Web of Science ®Google Scholar
• Toda M, Okubo S, Hara Y, Shimamura T. [Antibacterial and bactericidal activities of tea extracts and catechins against methicillin resistant Staphylococcus aureus]. Nippon Saikingaku Zasshi. Sep 1991;46(5):839–845. Japanese.
   Google Scholar
• Iinuma M, Tanaka T, Mizuno M, Yamamoto H, Kobayashi Y, Yonemori S. Phenolic constituents in Erythrina x bidwilli and their activity against oral microbial organisms. Chem Pharm Bull (Tokyo). 1992;40(10):2749–2752.
   Web of Science ®Google Scholar
• Kuroyanagi M, Arakawa T, Hirayama Y, Hayashi T. Antibacterial and antiandrogen flavonoids from Sophora flavescens. J Nat Prod. 1999;62(12):1595–1599.
   PubMed Web of Science ®Google Scholar
• Kubo M, Matsuda H, Tanaka M, et al. Studies on Scutellariae radix. VII. Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo). 1984;32(7):2724–2729.
   Google Scholar
• Yamada H, Takuma N, Daimon T, Hara Y. Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: a prospective clinical study. J Altern Complement Med. 2006;12(7):669–672.
   PubMed Web of Science ®Google Scholar
• Levy R, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, doubleblind pilot study. Nutr Res. 2009;29(5):298–304.
   Web of Science ®Google Scholar
• Pillai L, Burnett BP, Levy RM. Open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin: the GOAL study. Curr Med Res Opin. 2010; 26(5):1055–1063.
   PubMed Web of Science ®Google Scholar